Emergent BioSolutions Inc

Emergent BioSolutions is a biopharmaceutical organisation specialising in the development and manufacture of antibody therapeutics, such as vaccines and biodefence equipment. Founded in 1998, this multinational organisation is based in Gaithersburg, Maryland, USA. Although the highest concentration of company operations is based in the United States, Emergent BioSolutions has manufacturing, administrative, and development facilities all over the globe, including Canada, Portugal, and Singapore. As a leader in the development and manufacture of immunobiotics and biodefence therapeutics, Emergent BioSolutions collaborates with the broader industry, governments, and healthcare sectors. In June 2020, Emergent BioSolutions signed a five-year contract with Janssen Pharmaceuticals, Inc. part of Johnson and Johnson for the manufacture and rollout of a Covid-19 vaccine. This deal was reported to be worth $480m over 2 years. The company manufactures medicines for infectious diseases like cholera and typhoid, and Narcan for the emergency treatment of opioid overdoses. In addition, the company produces the only anthrax vaccine licensed by the U.S. Food and Drug Administration. With revenue exceeding $1.5bn in 2020, this organisation’s competitors in the industry include Novavax, Moderna, and Inovio. Emergent BioSolutions trades on the NYSE under the ticker EBS. Monitor the EBS share price by adding it to your eToro watchlist.